Core Insights - Micron Brain Science (02172) reported a mid-year performance for 2025, with revenue approximately 383 million yuan, a year-on-year decrease of 6.2% [1] - The company's profit attributable to equity shareholders was 92.923 million yuan, down 35.25% year-on-year, with earnings per share at 0.16 yuan [1] International Business Performance - The international business segment continued to show strong growth, with overseas revenue reaching 47.1 million yuan, an increase of 67.4% compared to the same period last year [1] - Profits from the international business division experienced rapid growth, indicating a successful expansion strategy [1] Product and Market Expansion - As of the end of the reporting period, the company had eight products launched internationally, achieving commercialization in 34 overseas countries or regions [1] - The products cover nine countries that rank among the top ten globally in terms of neurosurgical procedures, highlighting the company's competitive positioning [1] - The company secured nine product registration certificates in various overseas markets, laying a solid foundation for scaling up international revenue [1]
微创脑科学公布中期业绩 权益股东应占溢利9292.3万元 同比减少35.25%